Search - tctmd.com

Displaying 301 - 320 of 716

Sort: Relevancy | Date

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

Presentation SIF 2019

Women & Heart Disease

Presenter: Danielle Stearns

March 29, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

Advertisement

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

New Clarity on Patients at High Risk for Bleeding After PCI

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Women & Heart Disease

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content